• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

July 9, 2018
Company Drug/Device Medical Condition Status
Prana Biotechnology Ltd PBT434 Parkinsonian diseases Phase I trial initiated
Poxel SA Imeglimin Metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) Phase III trial initiated enrolling 403 subjects in the U.S.
Cellerant Therapeutics, Inc. romyelocel-L (human myeloid progenitor cells) serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy RMAT designation granted by the FDA
Merck & Company KEYTRUDA in combination with carboplatin-paclitaxel or nab-paclitaxel First-line treatment for metastatic squamous non-small cell lung cancer (NSCLC) Priority Review granted for sBLA by the FDA
Merz Neurosciences Xeomin (incobotulinumtoxinA) chronic drooling in adults with neurodegenerative diseases sBLA approved by the FDA
Compugen Ltd COM701 (first-in-class immunioncology therapeutic antibody targeting PVRIG in patients advanced solid tumors IND clearance granted by the FDA
Elite Pharmaceuticals, Inc. generic Percocet (Oxycodone Hydrochloride and Acetaminophen, USP CII) management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate aNDA approval granted by the FDA
Acadia Pharmaceuticals Inc. NUPLAZID (pimavanserin) capsule Parkinson’s disease psychosis Approval granted by the FDA
Pulmonx Inc. Zephyr Endobronchial Valve (Zephyr Valve) severe emphysema Approval granted by the FDA
Dermira Qbrexza excessive underarm sweating due to primary axillary hyperhidrosis Approval granted by the FDA
ReCor Medical Paradise Ultrasound Denervation System treatment of Hypertension Approval granted by the FDA
Alkermes plc Aristada Initio (aripiprazole lauroxil) schizophrenia in adults Approval granted by the FDA

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing